Switch to:
Also traded in: Germany, Singapore, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.15
LZAGY's Cash-to-Debt is ranked lower than
84% of the 999 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.87 vs. LZAGY: 0.15 )
Ranked among companies with meaningful Cash-to-Debt only.
LZAGY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.14 Max: No Debt
Current: 0.15
Equity-to-Asset 0.33
LZAGY's Equity-to-Asset is ranked lower than
80% of the 958 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.54 vs. LZAGY: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
LZAGY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.33 Max: 0.5
Current: 0.33
0.3
0.5
Interest Coverage 7.44
LZAGY's Interest Coverage is ranked lower than
74% of the 1106 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 32.49 vs. LZAGY: 7.44 )
Ranked among companies with meaningful Interest Coverage only.
LZAGY' s Interest Coverage Range Over the Past 10 Years
Min: 2.13  Med: 5.18 Max: 7.63
Current: 7.44
2.13
7.63
Piotroski F-Score: 6
Altman Z-Score: 2.68
Beneish M-Score: -2.92
WACC vs ROIC
6.92%
11.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 13.48
LZAGY's Operating Margin % is ranked higher than
77% of the 975 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 6.87 vs. LZAGY: 13.48 )
Ranked among companies with meaningful Operating Margin % only.
LZAGY' s Operating Margin % Range Over the Past 10 Years
Min: 7.06  Med: 11.44 Max: 15.02
Current: 13.48
7.06
15.02
Net Margin % 9.19
LZAGY's Net Margin % is ranked higher than
74% of the 976 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.78 vs. LZAGY: 9.19 )
Ranked among companies with meaningful Net Margin % only.
LZAGY' s Net Margin % Range Over the Past 10 Years
Min: 2.43  Med: 6.9 Max: 14.27
Current: 9.19
2.43
14.27
ROE % 17.57
LZAGY's ROE % is ranked higher than
81% of the 961 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 8.18 vs. LZAGY: 17.57 )
Ranked among companies with meaningful ROE % only.
LZAGY' s ROE % Range Over the Past 10 Years
Min: 4.11  Med: 11.75 Max: 22.52
Current: 17.57
4.11
22.52
ROA % 5.81
LZAGY's ROA % is ranked higher than
63% of the 1000 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.12 vs. LZAGY: 5.81 )
Ranked among companies with meaningful ROA % only.
LZAGY' s ROA % Range Over the Past 10 Years
Min: 1.3  Med: 4.04 Max: 7.45
Current: 5.81
1.3
7.45
ROC (Joel Greenblatt) % 39.47
LZAGY's ROC (Joel Greenblatt) % is ranked higher than
88% of the 993 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 12.99 vs. LZAGY: 39.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LZAGY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.93  Med: 12.67 Max: 39.47
Current: 39.47
7.93
39.47
3-Year Revenue Growth Rate -1.50
LZAGY's 3-Year Revenue Growth Rate is ranked lower than
62% of the 917 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.50 vs. LZAGY: -1.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LZAGY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 5.7 Max: 12.8
Current: -1.5
-2.3
12.8
3-Year EBITDA Growth Rate 3.30
LZAGY's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 816 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 8.80 vs. LZAGY: 3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LZAGY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -12.4  Med: 3.3 Max: 16.8
Current: 3.3
-12.4
16.8
3-Year EPS without NRI Growth Rate 16.20
LZAGY's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 744 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 9.20 vs. LZAGY: 16.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LZAGY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.9  Med: 1.9 Max: 28.2
Current: 16.2
-32.9
28.2
GuruFocus has detected 6 Warning Signs with Lonza Group Ltd $LZAGY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LZAGY's 10-Y Financials

Financials (Next Earnings Date: 2017-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Chemicals » Specialty Chemicals  
Compare:OTCPK:BLGA » details
Traded in other countries:LO3.Germany, O6Z.Singapore, LONN.Switzerland, 0QNO.UK,
Lonza Group AG is a supplier of biopharmaceuticals to the pharmaceutical and biotechnology industries. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients.

Lonza Group is a custom drug manufacturer and it also produces microbicides and other chemicals for the water treatment, personal care, health and hygiene, and industrial preservation markets. The firm is organized into two market-focused segments: Pharma and Biotech, and Specialty Ingredients. The majority of Lonza's products and services are sold to pharmaceutical companies, academic and government research organizations, and consumer goods and industrial companies.

Ratios

vs
industry
vs
history
PE Ratio 27.00
LZAGY's PE Ratio is ranked lower than
67% of the 1168 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 19.09 vs. LZAGY: 27.00 )
Ranked among companies with meaningful PE Ratio only.
LZAGY' s PE Ratio Range Over the Past 10 Years
Min: 8.61  Med: 24.37 Max: 69.7
Current: 27
8.61
69.7
Forward PE Ratio 17.83
LZAGY's Forward PE Ratio is ranked lower than
56% of the 146 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 16.67 vs. LZAGY: 17.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.00
LZAGY's PE Ratio without NRI is ranked lower than
64% of the 960 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 19.32 vs. LZAGY: 27.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
LZAGY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.61  Med: 24.47 Max: 69.7
Current: 27
8.61
69.7
Price-to-Owner-Earnings 24.89
LZAGY's Price-to-Owner-Earnings is ranked lower than
63% of the 491 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 18.64 vs. LZAGY: 24.89 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LZAGY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.22  Med: 77.1 Max: 243.12
Current: 24.89
9.22
243.12
PB Ratio 4.74
LZAGY's PB Ratio is ranked lower than
83% of the 1206 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.89 vs. LZAGY: 4.74 )
Ranked among companies with meaningful PB Ratio only.
LZAGY' s PB Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.62 Max: 4.75
Current: 4.74
0.81
4.75
PS Ratio 2.55
LZAGY's PS Ratio is ranked lower than
75% of the 1177 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.31 vs. LZAGY: 2.55 )
Ranked among companies with meaningful PS Ratio only.
LZAGY' s PS Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.66 Max: 3.25
Current: 2.55
0.63
3.25
Price-to-Free-Cash-Flow 20.34
LZAGY's Price-to-Free-Cash-Flow is ranked lower than
59% of the 529 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 16.88 vs. LZAGY: 20.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LZAGY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.17  Med: 20.39 Max: 234.99
Current: 20.34
6.17
234.99
Price-to-Operating-Cash-Flow 13.11
LZAGY's Price-to-Operating-Cash-Flow is ranked lower than
67% of the 620 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 9.20 vs. LZAGY: 13.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LZAGY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.47  Med: 11.09 Max: 36.19
Current: 13.11
3.47
36.19
EV-to-EBIT 21.37
LZAGY's EV-to-EBIT is ranked higher than
77% of the 1212 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 14.79 vs. LZAGY: 21.37 )
Ranked among companies with meaningful EV-to-EBIT only.
LZAGY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 20.2 Max: 32.6
Current: 21.37
8.4
32.6
EV-to-EBITDA 21.37
LZAGY's EV-to-EBITDA is ranked higher than
63% of the 1247 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 10.65 vs. LZAGY: 21.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
LZAGY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 10.8 Max: 21.39
Current: 21.37
4.9
21.39
PEG Ratio 12.81
LZAGY's PEG Ratio is ranked lower than
88% of the 437 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.96 vs. LZAGY: 12.81 )
Ranked among companies with meaningful PEG Ratio only.
LZAGY' s PEG Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.3 Max: 16.52
Current: 12.81
0.55
16.52
Shiller PE Ratio 38.05
LZAGY's Shiller PE Ratio is ranked lower than
53% of the 187 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 36.92 vs. LZAGY: 38.05 )
Ranked among companies with meaningful Shiller PE Ratio only.
LZAGY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.44  Med: 32.37 Max: 38.95
Current: 38.05
19.44
38.95
Current Ratio 1.49
LZAGY's Current Ratio is ranked lower than
63% of the 859 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.80 vs. LZAGY: 1.49 )
Ranked among companies with meaningful Current Ratio only.
LZAGY' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.31 Max: 2.02
Current: 1.49
0.94
2.02
Quick Ratio 1.49
LZAGY's Quick Ratio is ranked higher than
59% of the 859 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.32 vs. LZAGY: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
LZAGY' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 0.94 Max: 2.02
Current: 1.49
0.6
2.02
Days Inventory 82.41
LZAGY's Days Inventory is ranked lower than
65% of the 940 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 64.70 vs. LZAGY: 82.41 )
Ranked among companies with meaningful Days Inventory only.
LZAGY' s Days Inventory Range Over the Past 10 Years
Min: 82.41  Med: 112.3 Max: 123.17
Current: 82.41
82.41
123.17
Days Sales Outstanding 50.12
LZAGY's Days Sales Outstanding is ranked higher than
65% of the 781 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 58.95 vs. LZAGY: 50.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
LZAGY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.12  Med: 60.43 Max: 94.23
Current: 50.12
50.12
94.23
Days Payable 40.31
LZAGY's Days Payable is ranked lower than
61% of the 740 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 49.46 vs. LZAGY: 40.31 )
Ranked among companies with meaningful Days Payable only.
LZAGY' s Days Payable Range Over the Past 10 Years
Min: 29.47  Med: 37.08 Max: 53.87
Current: 40.31
29.47
53.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.38
LZAGY's Dividend Yield % is ranked lower than
63% of the 1115 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.81 vs. LZAGY: 1.38 )
Ranked among companies with meaningful Dividend Yield % only.
LZAGY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.96  Med: 1.92 Max: 6.38
Current: 1.38
0.96
6.38
Dividend Payout Ratio 0.37
LZAGY's Dividend Payout Ratio is ranked lower than
58% of the 741 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.32 vs. LZAGY: 0.37 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LZAGY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 1.29
Current: 0.37
0.22
1.29
3-Year Dividend Growth Rate 5.20
LZAGY's 3-Year Dividend Growth Rate is ranked lower than
56% of the 537 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 7.50 vs. LZAGY: 5.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
LZAGY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.1 Max: 10.4
Current: 5.2
0
10.4
Forward Dividend Yield % 1.38
LZAGY's Forward Dividend Yield % is ranked lower than
67% of the 1089 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.93 vs. LZAGY: 1.38 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.78
LZAGY's 5-Year Yield-on-Cost % is ranked lower than
59% of the 1273 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.20 vs. LZAGY: 1.78 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LZAGY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.24  Med: 2.47 Max: 8.22
Current: 1.78
1.24
8.22
3-Year Average Share Buyback Ratio -0.20
LZAGY's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 484 Companies
in the Global Specialty Chemicals industry.

( Industry Median: -1.30 vs. LZAGY: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LZAGY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.7  Med: 0.2 Max: 1.5
Current: -0.2
-3.7
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 4.74
LZAGY's Price-to-Tangible-Book is ranked lower than
78% of the 1139 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.07 vs. LZAGY: 4.74 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LZAGY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86  Med: 3.35 Max: 47.44
Current: 4.74
0.86
47.44
Price-to-Intrinsic-Value-Projected-FCF 2.11
LZAGY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 689 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.49 vs. LZAGY: 2.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LZAGY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 2.11 Max: 2.86
Current: 2.11
0
2.86
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.52
LZAGY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
84% of the 98 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.62 vs. LZAGY: 2.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.54
LZAGY's Price-to-Median-PS-Value is ranked lower than
99.99% of the 1127 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.43 vs. LZAGY: 1.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LZAGY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.89 Max: 1.54
Current: 1.54
0
1.54
Price-to-Graham-Number 2.39
LZAGY's Price-to-Graham-Number is ranked lower than
74% of the 889 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.34 vs. LZAGY: 2.39 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LZAGY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.75  Med: 1.65 Max: 7.99
Current: 2.39
0.75
7.99
Earnings Yield (Greenblatt) % 4.68
LZAGY's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 1334 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 6.06 vs. LZAGY: 4.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LZAGY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.1  Med: 4.9 Max: 12
Current: 4.68
3.1
12
Forward Rate of Return (Yacktman) % 5.46
LZAGY's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 589 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 8.16 vs. LZAGY: 5.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LZAGY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.8  Med: 4.5 Max: 17
Current: 5.46
-3.8
17

More Statistics

Revenue (TTM) (Mil) $3,991
EPS (TTM) $ 0.70
Beta0.95
Short Percentage of Float0.00%
52-Week Range $15.27 - 19.65
Shares Outstanding (Mil)522.83

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4,053 4,784 5,484
EPS ($) 0.82 1.02 1.13
EPS without NRI ($) 0.82 1.02 1.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.16%
Dividends per Share ($) 0.27 0.27 0.27
» More Articles for LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonza Group AG : Overvalued relative to peers, but good fundamentals Mar 15 2017
Lonza Group AG :LZAGY-US: Earnings Analysis: For the six months ended December 31, 2016 : March 6,... Mar 06 2017
Actelion, Syngenta takeovers set to shake up Swiss SMI index Jan 31 2017
Lonza Group AG : Neutral outlook but great fundamentals Jan 06 2017
Lonza Concludes Divestment of Peptides Business and Operations in Braine-l’Alleud, Belgium, to... Jan 04 2017
Lonza concludes peptides business sale, books charges Jan 04 2017
Lonza to buy U.S. drug capsule maker Capsugel from KKR for $5.5 billion Dec 15 2016
Lonza to buy U.S. drug capsule maker Capsugel from KKR for $5.5 billion Dec 15 2016
Lonza to buy U.S. drug capsule maker Capsugel from KKR for $5.5 billion Dec 15 2016
Capsugel S.A. Luxembourg -- Moody's reviews Capsugel's ratings for upgrade on pending acquisition by... Dec 15 2016
The Latest Punchy Pharma Price, Via KKR Dec 15 2016
5 Things You Must Know Before the Market Opens Thursday Dec 15 2016
European Bank Stocks Lead Markets Higher After Fed 'Dots' Roil Global Markets Dec 15 2016
Lonza Buys KKR-Backed Capsugel in $5.5 Billion Health Care Deal Dec 15 2016
UPDATE 1-Lonza to buy U.S. capsule maker Capsugel for $5.5 bln Dec 15 2016
Lonza Focuses on Health With $5.5 Billion Deal for Capsugel Dec 15 2016
Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and... Dec 15 2016
European shares pull back from 11-month high, oil stocks soar Dec 12 2016
EXCLUSIVE - Lonza says in talks to buy Capsugel; deal could top $5 billion - sources Dec 12 2016
EXCLUSIVE - Lonza says in talks to buy Capsugel; deal could top $5 billion - sources Dec 12 2016
5 Things You Must Know Before the Market Opens Monday Dec 12 2016
European shares pull back but oil rally limits losses Dec 12 2016
Exclusive: Lonza says in talks to buy Capsugel; deal could top $5 billion - sources Dec 12 2016
Exclusive: Lonza says in talks to buy Capsugel; deal could top $5 billion - sources Dec 12 2016
Exclusive: Lonza in talks to buy Capsugel for more than $5 billion - sources Dec 11 2016
Exclusive: Lonza in talks to buy Capsugel for more than $5 billion - sources Dec 11 2016
Lonza to Divest Peptides Business and Operations in Braine-l'Alleud, Belgium, to PolyPeptide Dec 07 2016
Lonza’s RAFT™ 3D Cell Culture System Enables Corneal Modeling for Research into Potential... Nov 14 2016
Lonza Launches New Preservation Website for Personal Care and Homecare Products Oct 31 2016
Lonza Expects to Reach 2018 Guidance One Year Ahead and Reports Strong Q3 Momentum Oct 27 2016
Lonza Prices CHF 250 Million Fve -Year Straight Bond with a 0.125% Coupon Oct 24 2016
Lonza Prices CHF 250 Million Five-Year Straight Bond with a 0.125% Coupon Oct 13 2016
Lonza Prices CHF 250 Million Five-Year Straight Bond with a 0.125% Coupo Oct 13 2016
Lonza Prices CHF 250 Million Five-Year Straight Bond with a 0.125% Coupon Oct 12 2016
ETF’s with exposure to Lonza Group AG : September 16, 2016 Sep 16 2016
Lonza and ImaginAb Announce Successful Completion of Accelerated Minibody Development and... Sep 15 2016
Lonza Completes Acquisition of InterHealth Nutraceuticals Sep 13 2016
Lonza to Offer Novel Anc-AAV Gene Therapy Technology Through Exclusive Licensing Agreement with... Sep 12 2016
Lonza Releases Second-Generation Immunogenicity A7 cs"> as Sep 08 2016
Lonza Reports Best First Half in History="i-prop=6 cs"> End ns/ops/li> Sep 08 2016
Lonza Releases Second-Generation Immunogenicity A3 on Wet Wipe Preser e lue="Nuy heapticsP s, V ’s... Sep 08 2016
Lonza Releases Second-Generation Immunogenicity A8 e Selection Tool at inonza Rep S Horrotho rabLonz... Sep 08 2016
Lonza Releases Second-Generation Immunogenicity A28 e Selection Tool atn at in-cosmetAeriosm oApn i... Sep 08 2016
Lonza Releases Second-Generation Immunogenicity A1 et Wipe Preservatio c., E b Sep 08 2016
Lonza Releases Second-Generation Immunogenicity Assessment and Optimization Platform for Development... Sep 07 2016
Lonza to Demonstrate Capabilities in Non-Viral or Viral CAR-T Research and Manufacturing at CAR-TCR... Aug 31 2016
Lonza to Launch Upgraded FormulaProtect ® Preservative Selection Tool at in-cosmetics North America Aug 30 2016
Lonza buys InterHealth in health push Aug 15 2016
Lonza buys InterHealth in health push Aug 15 2016
Lonza to Acquire InterHealth for as Much as $300 Million Aug 15 2016
Lonza Group AG :LZAGY-US: Earnings Analysis: For the six months ended June 30, 2016 : July 26, 2016 Jul 26 2016
ETF’s with exposure to Lonza Group AG : July 21, 2016 Jul 21 2016
European shares rise on strong results from SAP and Lonza Jul 20 2016
European shares rise on strong results from SAP and Lonza Jul 20 2016
Exclusive: Lonza in bid to acquire Catalent - sources Apr 13 2016
Exclusive: Lonza in bid to acquire Catalent - sources Apr 13 2016
Exclusive: Lonza in bid to acquire Catalent - sources Apr 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)